Kiniksa Provides Timing of Second Half 2020 Clinical Data Readouts
- Rilonacept pivotal Phase 3 data in recurrent pericarditis expected in Q3 2020 - - Mavrilimumab Phase 2 data in GCA and KPL-404 Phase 1 data expected in Q4 2020 - - Management to provide a corporate update at the 41st Annual Goldman Sachs Global …